Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Average PT from Analysts

Aura Biosciences, Inc. (NASDAQ:AURA) has been assigned a consensus recommendation of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $23.00.

A number of equities research analysts recently issued reports on the stock. BTIG Research boosted their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a report on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Aura Biosciences in a research note on Thursday, November 14th. JMP Securities upped their target price on shares of Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, September 13th. Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Finally, Cowen reissued a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th.

Aura Biosciences Stock Down 2.8 %

NASDAQ AURA opened at $8.72 on Friday. The firm has a 50-day moving average price of $9.70 and a 200 day moving average price of $8.71. The stock has a market capitalization of $435.56 million, a P/E ratio of -5.04 and a beta of 0.27. Aura Biosciences has a 52-week low of $6.63 and a 52-week high of $12.38.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02. On average, equities research analysts expect that Aura Biosciences will post -1.66 earnings per share for the current fiscal year.

Insider Transactions at Aura Biosciences

In related news, CFO Julie B. Feder sold 25,131 shares of the company’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $12.03, for a total transaction of $302,325.93. Following the transaction, the chief financial officer now directly owns 134,276 shares of the company’s stock, valued at approximately $1,615,340.28. The trade was a 15.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Janet Jill Hopkins sold 11,822 shares of Aura Biosciences stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.36, for a total transaction of $110,653.92. Following the sale, the insider now directly owns 151,693 shares of the company’s stock, valued at $1,419,846.48. This trade represents a 7.23 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 79,081 shares of company stock valued at $891,353. Company insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

Large investors have recently bought and sold shares of the business. Franklin Resources Inc. lifted its holdings in shares of Aura Biosciences by 14.8% during the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock worth $15,571,000 after buying an additional 215,597 shares during the last quarter. Long Focus Capital Management LLC boosted its stake in shares of Aura Biosciences by 113.4% in the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after purchasing an additional 561,766 shares in the last quarter. Geode Capital Management LLC grew its stake in Aura Biosciences by 4.1% during the third quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock worth $8,990,000 after buying an additional 39,379 shares during the last quarter. State Street Corp grew its position in Aura Biosciences by 3.7% during the 3rd quarter. State Street Corp now owns 754,803 shares of the company’s stock worth $6,725,000 after acquiring an additional 26,841 shares during the last quarter. Finally, Levin Capital Strategies L.P. increased its stake in shares of Aura Biosciences by 194.5% in the second quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock valued at $2,476,000 after buying an additional 216,266 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.